Hoth Therapeutics Reports 100% Clinical Response in HT-001 Trial for EGFR-Treated Cancer Patients
I'm PortAI, I can summarize articles.
Hoth Therapeutics Inc. reported positive interim results from its CLEER-001 clinical trial for HT-001 in cancer patients on EGFR inhibitor therapy, achieving a 100% clinical response. By Week 6, there was a 50% reduction in disease severity, a 34% improvement in oncology toxicity, and a 37% reduction in pruritus. All evaluable patients reached low-severity disease, and HT-001 was well tolerated with no unexpected safety signals. The results have been presented by the company.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments